North Tide Capital LLC maintained its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,000,000 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Gilead Sciences makes up 15.7% of North Tide Capital LLC’s holdings, making the stock its 3rd biggest holding. North Tide Capital LLC owned approximately 0.08% of Gilead Sciences worth $70,780,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Renaissance Technologies LLC lifted its holdings in Gilead Sciences by 35.0% in the 2nd quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after buying an additional 2,700,600 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. BlackRock Inc. lifted its holdings in Gilead Sciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after buying an additional 1,937,031 shares in the last quarter. Pioneer Investment Management Inc. lifted its holdings in Gilead Sciences by 84.0% in the 2nd quarter. Pioneer Investment Management Inc. now owns 3,493,148 shares of the biopharmaceutical company’s stock worth $247,245,000 after buying an additional 1,595,085 shares in the last quarter. Finally, Neuberger Berman Group LLC raised its stake in shares of Gilead Sciences by 90.9% in the 2nd quarter. Neuberger Berman Group LLC now owns 2,583,196 shares of the biopharmaceutical company’s stock valued at $182,839,000 after purchasing an additional 1,229,916 shares in the last quarter. Institutional investors and hedge funds own 76.23% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $73.09 on Tuesday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The stock has a market cap of $95,450.00, a P/E ratio of 7.86, a PEG ratio of -1.26 and a beta of 1.13. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same period last year, the firm posted $2.75 earnings per share. The business’s revenue was down 13.2% on a year-over-year basis. analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.85%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.66%.

A number of equities research analysts have recently issued reports on GILD shares. Argus upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Thursday, August 31st. Deutsche Bank restated a “buy” rating and issued a $81.00 target price on shares of Gilead Sciences in a research note on Thursday, August 31st. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 target price on the stock in a research note on Friday, October 13th. Credit Suisse Group restated an “outperform” rating and issued a $85.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $85.22.

In related news, insider John F. Milligan sold 220,000 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Over the last three months, insiders have sold 458,486 shares of company stock valued at $35,190,731. Company insiders own 1.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://theolympiareport.com/2017/12/05/north-tide-capital-llc-maintains-holdings-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.